BioCentury
ARTICLE | Translation in Brief

Boehringer double-dips into academia

Two academic deals for Boehringer Ingelheim

January 22, 2015 8:00 AM UTC

Boehringer Ingelheim GmbH announced separate research collaborations last week in immunomodulation and cancer with two U.S. universities. A deal with Yale University focuses on identifying targets for immune modulation in cancer, autoimmune and respiratory indications, while one with Vanderbilt University focuses on discovering new compounds against Ras oncogenes to treat cancer.

Under the terms of the Yale collaboration, Boehringer will fund joint research projects led by Lieping Chen, one of the researchers who first discovered the PD-1/PD-L1 immune checkpoint pathway in the 1990s. The company has an exclusive option to license resulting programs...